Katherine R W Emary

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2734078/publications.pdf

Version: 2024-02-01

1040056 8,292 9 9 citations h-index papers

g-index 9 9 9 14226 docs citations times ranked citing authors all docs

1474206

9

#	Article	IF	CITATIONS
1	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, The, 2021, 397, 99-111.	13.7	3,887
2	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet, The, 2020, 396, 1979-1993.	13.7	1,196
3	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet, The, 2021, 397, 881-891.	13.7	979
4	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nature Medicine, 2021, 27, 2032-2040.	30.7	900
5	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet, The, 2021, 397, 1351-1362.	13.7	540
6	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nature Medicine, 2021, 27, 270-278.	30.7	473
7	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nature Medicine, 2021, 27, 279-288.	30.7	265
8	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. Nature Communications, 2021, 12, 5861.	12.8	38
9	Vaccine nationalism and internationalism: perspectives of COVID-19 vaccine trial participants in the United Kingdom. BMJ Global Health, 2021, 6, e006305.	4.7	14